Clearity’s Perspective: If you or someone you love has been diagnosed with low-grade serous ovarian cancer (LGSOC), consider watching the recording of the OC Education webinar, “But This is Different: Understanding and Getting Support for the Unique Needs of People … Read more
by Huntsman Cancer Institute at the University of Utah
Newswise — A landmark study from researchers at Huntsman Cancer Institute at the University of Utah (the U), the Spencer Fox Eccles School of Medicine at the U, and Boston University … Read more
Clearity Perspective: When people like Connie share their ovarian cancer experience, it helps others learn about resources and feel less alone. Connie speaks about how she benefitted from Clearity’s Steps Through OC program by receiving personalized Ovarian Cancer Counseling. Clearity … Read more
By Ryan Scott
Patients who are heavily pretreated with recurrent low-grade serous ovarian cancer (LGSOC) had high response rates, regardless of the number of prior lines of therapy received, when treated with avutometinib (previously VS-6766) plus defactinib, according to data … Read more
By Ashley Chan
A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.
A phase 3 trial analyzing the treatment combination of avutometinib and defactinib compared with … Read more
By Mary Caffrey
Delayed diagnoses. Symptoms that are dismissed or misinterpreted. Feelings of anxiety because no one can offer a clear explanation for their condition.
These are just some of the experiences of women who have low-grade serous ovarian cancer … Read more
Clearity’s Perspective: The combination of avutometinib and defactinib has shown encouraging activity in Low-Grade Serous Ovarian Cancer. Updated results from the RAMP 201 trial suggest that the combination is active regardless of the number of prior therapies patients have received. … Read more
Treatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the … Read more
by Nichole Tucker
The success of BRAF/MEK combinations has led to the discovery of safety and preliminary activity with an investigational pan-RAF/MEK combination.
The investigational combination of lifirafenib (BGB-283) and mirdametinib (PD-0325901) has shown a favorable safety profile, as well … Read more
by Charles Bankhead
TAMPA, Fla. — About a fourth of patients with recurrent low-grade serous ovarian cancer (LGSOC) obtained durable responses to the combination of CDK4/6 inhibitor ribociclib (Kisqali) and letrozole, a small single-arm trial showed.
Overall, 23% of 48 … Read more
by Jordyn Sava
With encouraging response rates and a well-tolerated safety profile seen in RAMP-201, experts are hopeful for the accelerated approval of avutometinib plus defactinib for low-grade serous ovarian cancer.
The combination of avutometinib (VS-6766) with defactinib (VS-6063), as … Read more
by Caroline Seymour
The combination of abemaciclib and fulvestrant led to encouraging responses when used as neoadjuvant therapy which translated to high complete gross resection rates in patients with advanced, low-grade serous ovarian, fallopian tube, and peritoneal carcinoma.
The combination
by Rachel N. Grisham, M.D.
As summarized in this issue of The ASCO Post, the highly anticipated results of the GOG 281/LOGS study, which randomly assigned patients with recurrent low-grade serous ovarian cancer to the MEK inhibitor trametinib vs … Read more
by Jennifer Southall
Women with mitogen-activated protein kinase-mutated low-grade serous ovarian/peritoneal carcinoma experienced significantly longer PFS and OS compared with women without these mutations, according to study results.
The findings, presented during the Society of Gynecologic Oncology 2022 Annual … Read more
A drug currently used to treat skin and lung cancers has been found to slow the progression of a form of ovarian cancer and increase the number of patients who respond to treatment, a clinical trial has found.
As a … Read more
A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial – shrinking tumours in half of patients.
The combination of drugs – which both work by blocking signals cancer … Read more
A RAF/MEK plus FAK inhibitor combination will be given an expedited review by the FDA as therapy for patients with recurrent low-grade serous ovarian cancer.
By Audrey Sternberg
The combination of the RAF/MEK inhibitor, VS-6766, plus the FAK inhibitor, defactinib, … Read more
By Christina Bennett, MS
Patients with LGSC also had a significantly lower partial response rate with neoadjuvant therapy compared with patients with HGSC.
Patients with low-grade serous carcinoma of the ovary or peritoneum (LGSC) developed chemoresistance to neoadjuvant platinum-based therapy,
By Ian Ingram
For women with recurrent or persistent low-grade serous ovarian cancer (LGSOC), presence of a KRAS mutation appeared to predict benefit from binimetinib (Mektovi), a post-hoc analysis from the phase III MILO trial found.
Among women treated with … Read more
BOSTON–(BUSINESS WIRE)– Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
